Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Esprit Ma"'
Autor:
Pankit Vachhani, Esprit Ma, Tao Xu, Melissa Montez, Sarah Worth, Archibong Yellow‐Duke, Wei‐Han Cheng, Michael E. Werner, Jonathan Abbas, William Donnellan
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17914-17923 (2023)
Abstract Background This retrospective cohort study used an electronic health record‐derived, de‐identified, US patient‐level database to better understand the real‐world treatment experience, in a predominantly community setting (80.3% of pa
Externí odkaz:
https://doaj.org/article/3fb93e699c154e0782e4f2e27479dc7b
Autor:
Shebli Atrash, Evelyn M. Flahavan, Tao Xu, Esprit Ma, Sudeep Karve, Wan-Jen Hong, Gilbert Jirau-Lucca, Michael Nixon, Sikander Ailawadhi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 3, Pp 1-11 (2022)
Abstract A clearer understanding of the prognostic implications of t(11;14) in multiple myeloma (MM) is needed to inform current and future therapeutic options. We utilized real-world data from a US database to examine treatment patterns and outcomes
Externí odkaz:
https://doaj.org/article/9aa1eb73d99e4fc98d10477ab43f31d5
Autor:
Anda Gershon, Esprit Ma, Tao Xu, Melissa Montez, Kiran Naqvi, Grace Ku, Wendy Wei-Han Cheng, Evelyn M. Flahavan, Vamsi Kota, Daniel R. Greenwald
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 23:e222-e231
Autor:
Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally
Publikováno v:
Journal of Health Economics and Outcomes Research
**Objective:** To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective. **Methods:** A partitioned survival model used clinical outcomes for brentuximab vedotin from the pivotal phase-2 single-a
Externí odkaz:
https://doaj.org/article/7d27a3d6afc843208c70026aeb5511d8
Autor:
Keith W. Pratz, Xinglei Chai, Jipan Xie, Lei Yin, Xiaoyu Nie, Melissa Montez, Erica Iantuono, Lisa Downs, Esprit Ma
Publikováno v:
PharmacoEconomics. 40:777-790
Using individual patient-level data from the phase 3 VIALE-A trial, this study assessed the cost-effectiveness of venetoclax in combination with azacitidine compared with azacitidine monotherapy for patients newly diagnosed with acute myeloid leukemi
Publikováno v:
Blood. 140:11032-11034
Autor:
Michelle Choi, Jinlin Song, Cat N Bui, Esprit Ma, Xinglei Chai, Lei Yin, Keith A Betts, Tatyana Kapustyan, Melissa Montez, Thomas William LeBlanc
Publikováno v:
Journal of managed carespecialty pharmacy. 28(9)
Autor:
Pankit Vachhani, Esprit Ma, Tao Xu, Melissa Montez, Sarah Worth, Wei-Han Cheng, Michael Werner, Jonathan Abbas, William Donnellan
Publikováno v:
Blood. 140:683-684
Autor:
Linda Fleisher, Cassidy Kenny, Shayna Yeates Yeates, Zoe Landau, Patrick Kelly, Sarah Bass, Diane Ammerman, Canan Bilgin, Esprit Ma
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 32:B007-B007
(A) Although clinical trials (CTs) aim to establish new strategies for reducing cancer morbidity and mortality, participation remains suboptimal, especially for racial and ethnic minorities, and few studies have evaluated tailored communication tools
Autor:
Michael Nixon, Tao Xu, Evelyn M. Flahavan, Gilbert Jirau-Lucca, Wan-Jen Hong, Shebli Atrash, Sikander Ailawadhi, Sudeep Karve, Esprit Ma
Publikováno v:
Blood. 136:40-43
Introduction: MM is an incurable disease with risk categorizations by cytogenetic abnormalities. Prognostic implications of chromosome translocation t(11;14)+ are important to inform development of biomarker-targeted therapies such as the B-cell lymp